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Dapagliflozin is a sodium-glucose co-transporter 2 inhibitor which has been developed as 
oral glucose lowering drug. The original dose finding studies focused on optimal glycaemic 
effects. However, dapagliflozin also affects various cardio-renal risk markers and provides 
cardio-renal protection. In order to evaluate whether the currently registered doses of 5 and 
10 mg are optimal for cardio-renal efficacy and safety, we characterized the relationship 
between dapagliflozin exposure and non-glycaemic cardio-renal risk markers as well as 
adverse events.  
Methods 
Data were obtained from a pooled database of thirteen 24-week randomized controlled 
clinical trials of the clinical development program of dapagliflozin. The exposure-response 
relationship was quantified using population pharmacodynamic- and repeated time-to-event 
models. 
Results 
A dose of 10 mg dapagliflozin resulted in an average individual exposure of 638 ng.h/mL 
(95% Prediction Interval (PI): 354 to 1061 ng.h/mL), which translated in 71.2% (95% PI: 57.9 
to 80.5%), 61.1 % (95% PI: 58.0 to 64.8%), 91.3 % (95% PI: 85.4 to 94.6%) and 25.7% 
(95% PI: 23.5 to 28.3%) of its estimated maximum effect for fasting plasma glucose, 
haematocrit, serum creatinine and urinary albumin-creatinine ratio, respectively.  
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Conclusions 
We demonstrate that doses higher than 10 mg could provide additional beneficial effects in 
hematocrit, systolic blood pressure, urinary albumin creatinine ratio and uric acid, without 
obvious increases in the rate of adverse events. These results raise the question whether 
future outcome studies assessing the benefits of higher than currently registered 
dapagliflozin doses are merited. 
What is already known about this subject? 
Dapagliflozin is registered for clinical use at therapeutic doses of 5 and 10 mg once daily 
based on dose finding studies that targeted urinary glucose excretion as the primary 
glycaemic efficacy parameter.  
What this study adds 
This study indicates that the exposure-response relationship for glycaemic markers differs 
from the exposure-response relationships of cardio-renal risk markers. As a consequence, 
the optimal glycaemic dose of dapagliflozin might be different than the optimal cardio-renal 





This article is protected by copyright. All rights reserved. 
Introduction 
The sodium-glucose co-transporter-2 (SGLT-2), located in the S1 segment of the proximal 
tubule of the kidney, regulates glucose reabsorption and plays an important role in glucose 
homeostasis.[1] Inhibition of SGLT-2 by dapagliflozin causes glucosuria[2] and, in patients 
with type 2 diabetes, improvements in glycated haemoglobin (HbA1c) and fasting plasma 
glucose (FPG).[3-7]  
Favourable effects of dapagliflozin have been demonstrated on other cardio-renal risk 
markers including systolic blood pressure (SBP), hematocrit (HCT), albuminuria and uric 
acid (UA).[8, 9] The Dapagliflozin Effect on Cardiovascular Events - Thrombolysis in 
Myocardial Infarction (DECLARE-TIMI) 58 trial observed long-term improvements in heart 
failure and kidney outcomes with dapagliflozin once daily vs. placebo.[10-13] The modest 
reduction in HbA1c and the observed early time course of a reduction in events in the 
DECLARE-TIMI 58 trial as well as findings from other clinical trials indicate that these 
beneficial effects of dapagliflozin are unlikely explained by improvements in glycaemic 
control.[9, 14-16] Other mechanisms, such as the reduction of plasma volume as a 
consequence of the natriuretic effects of dapagliflozin, have been proposed to explain the 
beneficial effects of SGLT2 inhibitors on heart and kidney failure.[17]  
At present, dapagliflozin is registered for clinical use at therapeutic doses of 5 and 10 mg 
once daily based on dose finding studies that targeted urinary glucose excretion as the 
primary glycaemic efficacy parameter.[1, 2, 18, 19] As the efficacy of SGLT2 on clinical 
outcomes appears to be largely independent of glycaemic control, this raises the question 
whether glycaemic parameters are the most appropriate parameters to determine the 
optimal dose for dapagliflozin. We therefore aimed to characterize the exposure-response 
relationship between dapagliflozin and a range of cardio-renal risk markers as well as 
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Materials and Methods 
The 13 phase II/III trials of the dapagliflozin clinical development program that formed the 
basis for the dose registration of dapagliflozin were included in this analysis, an overview of 
the included studies is depicted in Table 1. All studies received approval of the final protocol 
by an independent ethics committee or institutional review board. Studies were performed in 
accordance with the ethical principles that have their origin in the Declaration of Helsinki and 
that are consistent with International Conference on Harmonization/Good Clinical Practice 
(GCP) and applicable regulatory requirements and the AstraZeneca policy on bioethics. 
Estimation of exposure to dapagliflozin 
Pharmacokinetic data were not available for all patients in our analysis. However, the 
pharmacokinetics of dapagliflozin have been quantified in a previous study of Van der Walt 
et al. using a semi-mechanistic population pharmacokinetic model.[20] Child-Pugh score, 
ideal bodyweight, baseline creatinine clearance and age were identified in this model as 
covariates that explained variability in the pharmacokinetic profile between patients. These 
individual patient characteristics were available for all patients in our analysis, therefore, we 
used this pharmacokinetic model to predict the individual exposure to dapagliflozin. For each 
patient in our analysis, 1000 simulations including interindividual variability were performed.  
The median predicted Area Under the Curve for 24 hour at steady state (AUC0-24) for each 
individual was estimated.  
Modelling of cardio-renal risk markers 
Population pharmacodynamic analyses explored the exposure-response relationship 
between dapagliflozin and various (cardio-renal) risk markers. Favourable effects have been 
demonstrated for serum creatinine (SCr), HCT, SBP, Urinary albumin-creatinine ratio 
(UACR) and UA, and were therefore selected for the current analysis. In addition, FPG was 
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used in the dose-response studies and therefore selected as glycaemic parameter in this 
study.  
For each trial, observations during the randomized period were included in the analysis. 
Observations after rescue medication were excluded from the analysis and, for the UACR-
dataset, only patients with microalbuminuria (UACR > 30 mg/g, n = 1859) at baseline were 
included. UACR observations were log-transformed. For each of the analyses datasets, 
AUC0-24 was assumed to be zero at baseline and, after baseline, the individual model 
predicted AUC0-24 was incorporated in the datasets.  
A non-linear mixed effects modeling approach was used to develop a population 
pharmacodynamic model for each (cardio-renal) risk marker. First-order conditional 
estimation with interaction was used to obtain parameter estimates. An individual baseline 
parameter was estimated for each patient in the placebo-group as a first step in the model 
development. Subsequently, several empirical structural models were evaluated in the 
placebo-group to evaluate the effect of placebo administration and disease 
progression;Linear, power, exponential, Emax, Gompertz, Weibull, Bateman and cosine 
functions were evaluated both additive and proportional to the estimated baseline 
parameter.[21] Interindividual variability (IIV) was formally tested on model parameters using 
a normal or log-normal distribution. Also, covariance between model parameters was 
explored. After evaluating the placebo response, patients were stratified by treatment; 
dapagliflozin or placebo. The effect of treatment was then tested on the structural model 
parameters by estimating a drug effect per model parameter. The relationship between 
individual dapagliflozin exposure (AUC0-24) and response was explored using linear, log-
linear or Emax functions. Additive, proportional and combined error models were evaluated 
to describe the residual variability. Finally, a covariate step was performed by plotting 
interindividual variability parameters versus covariates. When r2 > 0.15 and p < 0.05, 
covariate relationships were formally tested in the model. Covariates evaluated were: age, 
bodyweight, body mass index, compliance, duration of diabetes, ethnicity, FPG, 
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haemoglobin, HbA1c, height, ideal bodyweight, liver function markers, SBP, SCr, race, 
region, sex, study identifier, UA. Model selection and evaluation was based on numerical 
and graphical evaluation as described by Byon et al.[22] 
Modelling of adverse events 
Repeated time-to-event models were developed to investigate the exposure-response 
relationship between dapagliflozin and the probability of developing a genital tract infection 
(GTI) and urinary tract infection (UTI) in the 24 week study period. Studies MB102014, 
MB102067 and MB102080 were included in the repeated time-to-event analysis, since these 
datasets contained information about adverse events. Model parameters were obtained 
using the Laplacian estimation method. It was anticipated that the probability of developing 
an event was relatively low for both GTIs and  UTIs. Therefore, at first, several structural 
models were evaluated to describe the hazard for each event of interest using the full 
datasets. Constant, Gompertz and Weibull functions were evaluated to describe the hazard.  
Second, the effect of dapagliflozin was explored using a similar approach as described 
above for the population pharmacodynamic models. The exposure-response relationship 
was evaluated using linear, log-linear or Emax functions proportional to the hazard function. 
Model selection and evaluation was based on numerical diagnostics (i.e. the change in 
MOFV and reduction in RSE of the population parameter estimates) and graphically using 
survival based visual predictive checks. Third, covariates were evaluated graphically by 
stratification of the survival based visual predictive checks. The covariate was formally tested 
if a discrepancy was discovered between observed versus predicted survival.  
Exploring the exposure-response relationships 
Simulations with the final population pharmacodynamic models were performed to compare 
the exposure-response relationships between the cardio-renal risk markers. We evaluated 
the exposure-response relationship on week 24, as most of the clinical trials included in our 
analysis had a follow-up of 24 weeks.  For each model, 1000 patients were simulated per 
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dapagliflozin dose group. Each simulation included interindividual random effects and 
assumed similar exposure and covariate distributions as observed in the population per dose 
group. For each cardio-renal risk marker, we estimated the maximum effect of dapagliflozin 
assuming an infinite high exposure (exposure of 1.000.000 ng.h/mL). For both UTI and GTI, 
we estimated the probability of developing an event during 24 weeks. This probability was 
estimated by predicting the number of events in 24 weeks and dividing this number by the 
total number of subjects.   
Software  
All data preparation and presentation was performed using R version 3.4.2 (R Foundation for 
Statistical Computing, Vienna, Austria). NONMEM version 7.3.0 (ICON Development 
Solutions, Ellicott City, MD USA) was used for the pharmacokinetic simulations, 
development of population pharmacodynamic models and repeated time-to-event models 
and all simulations of the final models. 
 
Results 
Demographics and estimation of exposure to dapagliflozin 
A total of 7005 patients with type 2 diabetes mellitus randomized in 13 phase II/III 
randomized controlled trials of 12-24 week duration were included in the analysis. Baseline 
characteristics by treatment assignment are displayed in table 2. A dose range of 1.0 to 50.0 
mg was evaluated, although a majority of patients received 5.0 mg (14.4%) or 10.0 mg 
(37.4%) dapagliflozin once daily. No apparent differences are visible between treatment 
groups in the patient characteristics, except for a difference in the duration of type 2 diabetes 
mellitus (Table 2). The individual median predicted dapagliflozin systemic exposure, 
stratified by treatment group, demonstrated that the exposure to dapagliflozin is dose 
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proportional and the variability is such that dapagliflozin systemic exposure overlaps 
between the different treatment groups (Figure 1).  
Modelling of cardio-renal risk markers 
A majority of patients was included for all risk markers (table 3), except for UACR. Patient 
numbers per study have been provided in supplement 5. Several empirical population 
pharmacodynamic models were developed to describe the trend over time for each cardio-
renal marker for each subject included in the analysis. A brief description of the model 
development, model structure, model parameters and visual predictive checks stratified by 
treatment are displayed in supplemental figures 1-6 and supplemental tables 1-6 for all 
population pharmacodynamic models.  
Table 3 provides an overview of the structures used in the population pharmacodynamic 
models. An individual baseline parameter was estimated for each patient. For all models, the 
individual baseline parameters were best described using a log-normal distribution, except 
for HCT which was best described using a normal distribution. A placebo response was 
identified for FPG and UACR, characterized by a proportional Weibull and power function 
respectively. Drug effects could be identified for each pharmacodynamic parameter of 
interest, which could also be related to individual exposure. In general, Emax or log-linear 
relationships were able to describe the exposure-response relationships. However, for HCT 
and SCr, drug effects were best described using a power- and a Bateman function, 
respectively. All goodness-of-fit plots demonstrate that the model predictions follow the 
central trend of the data, indicating appropriate structural models. No bias over time was 
observed in the conditional weighted residuals versus time plots. In general, model 
parameters were estimated with high precision (average Relative Standard Error (RSE) 
11.6%, highest RSE was 60.9%, see supplemental tables 1-6).  
Interindividual variability was identified on the baseline parameters of all models. In addition, 
interindividual variability could be identified on other model parameters for SCr, FPG, HCT 
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and UACR, but not for SBP and UA. Significant covariates that explained variability between 
patients in the different models were: age, bodyweight, duration of diabetes, serum 
creatinine, sex and uric acid (Table 3). Goodness-of-fit plots demonstrated that the individual 
model predictions followed the individual trend of the data. The residual error was estimated 
using either an additive, proportional or combined error model (Table 3).  
Modelling of adverse events 
For modelling of adverse events, data were available for 2430 out of the 7005 patients 
included in our analysis from studies MB102014, MB102067 and MB102080. A total of 77 
and 92 patients reported a GTI and UTI, respectively, during the study period of 24 weeks. 
Instead of time-to-event models that only include one observation per patient, we developed 
repeated time-to-event models that included all available observations. For GTI and UTI, a 
total of 87 and 108 events were observed during the clinical trials during the study period of 
24 weeks. A brief description of the model development, model structure, model parameters 
and visual predictive checks stratified by treatment are displayed in supplemental figures 7 
and 8, and supplemental tables 7 and 8. 
Table 3 provides an overview of the repeated time-to-event models for UTI and GTI. A 
Weibull model was used to describe the survival distribution over time for both GTI and UTI. 
Drug effects were identified for both GTI and UTI, which could also be related to individual 
exposure. For GTI, an Emax function was used to relate individual exposure to the 
probability of developing an event. For UTI, the individual dapagliflozin systemic exposure 
was log-linearly related to the probability of developing an event. Significant covariates that 
explained differences in the probability of developing an event were sex and region for both 
GTI and UTI. In addition, for UTI, the use of an Angiotensin Converting Enzyme (ACE) 
inhibitor was also a significant covariate. Both models were estimated with good precision 
(average RSE 32.7%, highest RSE was 72.42%, see supplemental table 7 and 8). 
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Furthermore, the goodness-of-fit plots indicate that the central trend of the data is 
adequately described by the model.  
Exploration of the exposure-response relationships 
Figure 2 demonstrates the exposure-response relationship between dapagliflozin and each 
of the pharmacodynamic markers of interest at week 24. The individual exposure for 5 mg 
dapagliflozin was on average 327 ng.h/mL (95% Prediction Interval (PI): 187 to 547 
ng.h/mL), which translated in 55.9% (95% PI: 42.0 to 68.0%), 57.6% (95% PI: 54.6 to 
60.3%) and 84.3% (95% PI: 75.5 to 90.0%) of its estimated maximum effect for FPG, HCT 
and SCr, respectively.  Furthermore, 10 mg dapagliflozin resulted in an average individual 
exposure of 638 ng.h/mL (95% PI: 354 to 1061 ng.h/mL), which translated in 71.2% (95% PI: 
57.9 to 80.5%), 61.1 % (95% PI: 58.0 to 64.8%) and 91.3 % (95% PI: 85.4 to 94.6%) of its 
estimated maximum effect for FPG, HCT and SCr, respectively.     
The effects of dapagliflozin on SBP, UA and UACR did not approach the maximum effect of 
dapagliflozin. For UACR, 10 mg dapagliflozin achieved 25.7% (95% PI: 23.5 to 28.3%) of the 
maximum effect. Moreover, for both SBP and UA, 10 mg dapagliflozin induced less than 
10% of the estimated maximum effect.  
The relationship between individual exposure to dapagliflozin and the probability of 
developing a GTI and UTI in 24 weeks is shown in figure 3. For GTI, the probability of 
developing an infection appeared to reach a maximum around an exposure of 500 ng.h/mL, 
which is covered by the individual exposures following a dose of 5.0 to 10.0 mg 
dapagliflozin. For UTI, the maximum probability seems not to have been reached as the 
trend of developing an UTI is still increasing at a maximum exposure of 1000 ng.h/mL.  
Discussion 
In this pooled analysis, we quantified the exposure-response relationship between 
dapagliflozin and several (cardio-renal risk) markers and adverse events. Dapagliflozin given 
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at 10 mg/day was close to its maximum effect for serum creatinine. For both fasting plasma 
glucose and hematocrit, 10 mg dapagliflozin resulted in effects that appeared to approach 
the maximum effect, although there was room for higher efficacy. For systolic blood 
pressure, uric acid and urinary albumin creatinine ratio, the effects of dapagliflozin 10 
mg/day reached less than 25.7% of their maximum effects, suggesting that a higher dose of 
dapagliflozin could confer additional effect. From a safety perspective, the probability of 
developing a genital tract infection reached a plateau around a dose of 5 to 10 mg. Since 
hematocrit, systolic blood pressure and urinary albumin creatinine ratio are strong risk 
markers for renal and heart failure outcomes, our results suggest that a higher dose of 
dapagliflozin may confer additional clinical benefit in the long-term. 
This exposure-response analysis contains 13 phase II and III trials of the clinical 
development program of dapagliflozin that investigated efficacy and safety in patients with 
type 2 diabetes mellitus. The included patient population of all studies demonstrated a broad 
range of patient characteristics, which were comparable amongst studies. Using a previously 
developed population pharmacokinetic model by van der Walt et al.[20], we were able to 
predict the individual exposure for each patient included in our analysis. Model simulation 
techniques resulted in an average individual exposure of 638 ng.h/mL and a 95% prediction 
interval ranging from 354 to 1061 ng.h/mL following a 10 mg dapagliflozin dose at steady 
state. The prediction interval is comparable to previously reported interindividual variability at 
steady state for a 10 mg dose[18], indicating the appropriateness of the model to predict 
individual exposures. In addition, a similar structural model was used in patients with type 1 
diabetes mellitus confirming the generalizability of the population pharmacokinetic 
model.[23]  
Favourable effects of dapagliflozin have been demonstrated on a range of cardio-renal risk 
markers including long-term improvements in heart failure and kidney outcomes which are 
unlikely explained by improvements in glycaemic control[13]. In our analysis, and as 
expected, the dose-response relationship between dapagliflozin and fasting plasma glucose 
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was in line with previous studies.[4] Interestingly, the exposure-response relationship for 
several other cardio-renal risk markers differed from fasting plasma glucose. As a 
consequence, for most cardio-renal risk markers the maximal effects were not yet achieved 
at the registered antihyperglycaemic dose. This effect is reminiscent of ACE-inhibitors and 
Angiotensin Receptor Blockers. Although these agents are registered as antihypertensive 
drugs, their benefits are likely mediated by their albuminuria lowering effect.[24] Dose-finding 
studies have demonstrated that higher than maximum antihypertensive doses of these drugs 
result in additional albuminuria reduction and long-term clinical benefits on kidney 
function.[25-27] Collectively, these data complicate the optimal dose finding for a new drug 
as the exposure-response relationship may be different among cardio-renal risk markers. 
Consequently, to determine the optimal dose of a new drug, the exposure-response 
relationships on a composite score including multiple pharmacodynamic efficacy and safety 
markers may be considered.[28]  
Establishing efficacy at higher doses should be weighed against the risk of developing more 
adverse events. We therefore characterized the relationship between exposure and adverse 
events with dapagliflozin.[13] For genital tract infections, the probability of developing an 
infection plateaued around a dose of 5 to 10 mg dapagliflozin. The probability of developing 
a urinary tract infection still increased at a dose of 10 mg dapagliflozin suggesting that based 
on our studies higher efficacy may occur at the expense of more urinary tract infections. We 
note however that the overall probability of developing an event was low for both genital and 
urinary tract infections limiting the precision of the estimated probabilities. In addition, 
although earlier clinical trials, including those used for our study, reported differences in 
incidence of urinary tract infections, the overall rate of these infections did not differ between 
SGLT2 and placebo treated patients in more recent cardiovascular outcome trials.[10, 12, 
13]  
The efficacy and safety of dapagliflozin as a treatment for CKD is currently being 
investigated in patients with and without diabetes in the Study to Evaluate the Effect of 
 
 
This article is protected by copyright. All rights reserved. 
Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic 
Kidney Disease  (Dapa-CKD, NCT03036150). In addition, the Study to Evaluate the Effect of 
Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in 
Patients With Chronic Heart Failure (Dapa-HF, NCT03036124) demonstrated that 
dapagliflozin reduced the risk of heart failure or cardiovascular death compared to 
placebo regardless of the presence of diabetes mellitus type 2.[16] In these studies 
patients without diabetes receive the highest approved antihyperglycaemic dapagliflozin 
dose of 10 mg/day. In patients without diabetes it is unlikely that dapagliflozin lowers Hba1c 
because of both decreased renal glucose filtration, reducing the drug’s efficacy to inhibit 
tubular glucose reabsorption, and increasing hepatic glucose production that compensates 
for the increased urinary glucose loss.[29, 30] The optimal dose for non-diabetic patients 
should therefore be based on other cardio-renal risk markers. Our study offers a first 
assessment on the exposure-response relationship for dapagliflozin for other cardio-renal 
risk markers but future dedicated dose finding studies would be required to identify the 
optimal dose that reduces the risk for heart failure and kidney outcomes in the non-diabetic 
populations.  
This study has limitations including that in our analysis we were not able to identify 
interindividual variability in SBP and UA response. A possible explanation for this 
phenomenon, is that both markers already reached a maximum effect when the first 
observation after baseline had been collected. In that case, more densely sampled data in 
the first week after administration of dapagliflozin would be required to fully characterize the 
effects in these markers over time. Also, we acknowledge that only a limited number of 
patients were included in the analysis that received a dapagliflozin dose higher than 10 mg 
possibly limiting the precision of the estimated maximum effect. From the simulated 
exposures, it is however clear that there is large overlap in individual exposure between the 
different dose levels. In addition, we only included six cardio-renal markers and two types of 
adverse events. Therefore, we might have missed important cardio-renal risk markers or 
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adverse events. Nonetheless, there was a clear difference between the exposure-response 
relationships, which could also be the case for other cardio-renal risk markers and adverse 
events. In the DECLARE-TIMI 58 trial, an increased risk of  diabetic ketoacidosis and genital 
tract infections was observed in patients using dapagliflozin.13 In the studies included in our 
analysis, there was only one event of diabetic ketoacidosis and therefore no model could be 
developed for this adverse event.  Future research will be necessary to quantify the 
influence of dose on diabetic ketoacidosis. Furthermore, a lot of covariates were screened 
during the analysis, however we cannot exclude that we missed important factors, such as 
smoking status, that could have affected the relationship between exposure and cardio-renal 
risk markers. Finally, in the exposure-response relationships for genital and urinary tract 
infections, Europeans versus non-Europeans appeared to be a significant covariate. There is 
no clear explanation for this finding and may be a chance finding due to the limited number 
of events.  
In conclusion, the exposure-response analysis demonstrates that the exposure-response 
relationship of dapagliflozin differs between various cardio-renal risk markers. A dose higher 
than 10 mg dapagliflozin could provide additional beneficial effects in fasting plasma 
glucose, hematocrit,  systolic blood pressure, albuminuria and uric acid. The exposure-
response relationship between dapagliflozin and adverse events demonstrated that a higher 
dose could be safe, as the overall incidence of developing an event was low. Given that the 
investigated cardio-renal risk markers are strong risk markers for cardiovascular and renal 
outcomes raises the question whether clinical outcome trials specifically assessing the 
benefits of higher than currently registered doses of dapagliflozin are needed. 
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and efficacy of the combination of 
metformin and dapagliflozin, 
versus dapagliflozin monotherapy 
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Table 2. Summary of demographic characteristics at baseline for the randomized 
population.  
Dose (mg) Placebo 1.0 2.5 5.0 10.0 20.0 50.0 Total 









































(15.3) 71 (9.4) 96 (9.5) 
187 
(7.1) 2 (3.4) 1 (1.8) 
534 
(7.6) 









































Duration of Diabetes 












(51.3) N/A N/A 
168.2 
(49.4) 
HbA1c (%) 8.2 (1.0) 7.8 (1.0) 8.2 (0.9) 8.3 (1.1) 8.3 (1.1) N/A N/A 8.2 (1.0) 
 
Serum creatinine 




































Uric Acid (mg/dL) 5.6 (1.6) 5.4 (1.4) 5.4 (1.4) 5.4 (1.6) 5.6 (1.5) N/A N/A 5.5 (1.6) 
         
The data are displayed as number of subjects (percentage of the population) or as mean (standard deviation) for 
continuous variables. N/A: Not available.   
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Table 3. Overview of model structure and number of patients per cardio-renal risk 
marker or adverse event. Serum creatinine (SCr), Fasting plasma glucose (FPG), Serum 
hematocrit (HCT), Systolic Blood Pressure (SBP), Urinary Albumin-Creatinine Ratio (UACR), 




Population pharmacodynamic models Repeated time-
to-event models 
SCr (n = 
7004) 
FPG (n = 
6613) 
HCT (n = 
7005) 
SBP (n = 
6814) 
UACR (n = 
1859) 











































































































































Additive  Combined N/A N/A 
N/A: Not applicable, DREC = Amplitude parameter of bateman function,  ALPHA = amplitude parameter of power 
function, SHP = shape parameter of Weibull function. 
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Figure 1. Relationship between dose and individual exposure (AUC0-24 at steady state) 
per treatment group. The points represent the predicted median AUC0-24 at steady state for 
each individual patient. The boxplot demonstrates the distribution of individual predicted 
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Figure 2. Exposure-Response relationships at week 24 for fasting plasma glucose (top 
left), hematocrit (top right), serum creatinine (middle left), urinary albumin-creatinine 
ratio (middle right), uric acid (bottom left) and systolic blood pressure (bottom right). 
The line demonstrates the exposure-response relationship for the typical individual, 
individual points demonstrate the individual predictions. The 90% prediction interval has 
been included, if applicable, as interindividual random effects could only be identified on 
baseline and could not be identified in drug response for systolic blood pressure and uric 
acid. In each plot, the relationship between dose and median predicted AUC0-24 is displayed 
for patients included in the pharmacodynamic datasets. Data were not available for 
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Figure 3. Exposure-Response relationship for genital (left) and urinary tract infections 
(right). The figures demonstrates the exposure-response relationship for the typical 
individual and are stratified by sex and region of inclusion. Non-European females (orange), 
non-European males (yellow), European female (purple) and European male (red) 
 
  
 
